Gallbladder Cancer Pipeline Review, H2 2012


#146065

109pages

Global Markets Direct

$ 2000

In Stock

 

Gallbladder Cancer Pipeline Review, H2 2012

 

Global Markets Directs, 'Gallbladder Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gallbladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gallbladder Cancer. Gallbladder Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Gallbladder Cancer.
  • A review of the Gallbladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Gallbladder Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 8
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gallbladder Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Gallbladder Cancer 11
Gallbladder Cancer Therapeutics under Development by Companies 13
Gallbladder Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Gallbladder Cancer Therapeutics Products under Development by Companies 21
Gallbladder Cancer Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Gallbladder Cancer Therapeutics Development 25
AstraZeneca PLC 25
Simcere Pharmaceutical Group 26
Gallbladder Cancer Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
vandetanib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
erlotinib hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Gemcitabine + Oxaliplatin + Erlotinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gemcitabine + Radiation Therapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sorafenib tosylate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
capecitabine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Gemcitabine + Capecitabine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Erlotinib + Gemcitabine + Oxaliplatin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
Gemcitabine + Cisplatin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
dolastatin 10 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Capecitabine + Gemcitabine + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
trastuzumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Recombinant Human Interleukin-12 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gemcitabine + Capecitabine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Zactima + Gemzar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gemcitabine + Cisplatin + Sorafenib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Gemcitabine + Cisplatin + S-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Recombinant Fowlpox-CEA(6D) + GM-CSF - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cyclophosphamide + Fludarabine + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation + Therapeutic Allogeneic Lymphocytes - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
Gemcitabine + Sorafenib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Avastin + Tarceva - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Eloxatin + Xeloda - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 68
S-1 + Gemcitabine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
fluorouracil - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
TS-1 + Gemcitabine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Capecitabine + Oxaliplatin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GEMOX - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Gemcitabine + Cisplatin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Gemcitabine + Alimta - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Gemcitabine + S-1 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Irinotecan + Gemcitabine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Gemcitabine + Cisplatin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Gemcitabine + Radiation Therapy - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Glivec + 5-Fluorouracil + Leucovorin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Pralatrexate + Docetaxel - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Anti-Thymocyte Globulin + Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Fludarabine + Peripheral Stem Cell Transplantation - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
Gemcitabine + Capecitabine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
porfimer sodium - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Gemcitabine Hydrochloride + Oxaliplatin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Modified FOLFOX6 + AZD2171 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Docetaxel + Oxaliplatin - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Gemcitabine + S-1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
gemcitabine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Gemcitabine + Oxaliplatin - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
GEMOX + Cetuximab - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Gemcitabine + Cisplatin + S-1 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Gemcitabine + Cisplatin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Gemox 85 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Gemcitabine + Oxaliplatin + Radiation therapy - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Gallbladder Cancer Therapeutics Drug Profile Updates 103
Gallbladder Cancer Therapeutics Discontinued Products 105
Gallbladder Cancer Therapeutics - Dormant Products 106
 

Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109


Number of Products Under Development for Gallbladder Cancer, H2 2012 11
Products under Development for Gallbladder Cancer Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 24
AstraZeneca PLC, H2 2012 25
Simcere Pharmaceutical Group, H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Gallbladder Cancer Therapeutics Drug Profile Updates 103
Gallbladder Cancer Therapeutics Discontinued Products 105
Gallbladder Cancer Therapeutics Dormant Products 106
Gallbladder Cancer Therapeutics Dormant Products (Contd..1) 107


Number of Products under Development for Gallbladder Cancer, H2 2012 11
Products under Development for Gallbladder Cancer Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32